GAITHERSBURG, Md., April 7 /PRNewswire-FirstCall/ -- MedImmune, Inc.'s
(Nasdaq: MEDI) first quarter financial results for 2004 will be announced on
Wednesday, April 21, 2004 before the opening of the U.S. financial markets.
The company will also host a conference call and live audio webcast at 8:00
a.m. eastern time following the announcement. During the conference call,
MedImmune's management will discuss the financial results for the quarter and
The press release and the live webcast will be accessible through the
Investor Relations section on MedImmune's website at www.medimmune.com.
Following the live webcast, an archived version of the call will be available
on MedImmune's website until April 28, 2004.
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets four
products, Synagis(R) (palivizumab), Ethyol(R) (amifostine), FluMist(TM)
(Influenza Virus Vaccine Live, Intranasal), and CytoGam(R) (cytomegalovirus
immune globulin intravenous (human)), and has additional products in clinical
testing. MedImmune employs approximately 1,800 people, is headquartered in
Gaithersburg, Maryland, and has additional operations in Frederick, Maryland,
as well as Pennsylvania, California, the United Kingdom and the Netherlands.
For more information on MedImmune and its products, visit the company's
website at www.medimmune.com.
This announcement may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties. Such
statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the company's filings with the U.S. Securities and
Exchange Commission. The company is developing several products for potential
future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or
that, even if such regulatory clearance were received, such products would
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
/CONTACT: Media: Jamie Lacey, +1-301-398-4035 or Investors: John
Filler, +1-301-398-4086, both of MedImmune, Inc./
/Web site: http://www.medimmune.com/
CO: MedImmune, Inc.
IN: HEA MTC BIO
SU: CCA MAV
-- DCW024 --
5528 04/07/2004 09:22 EDT http://www.prnewswire.com